Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.58
- Piotroski Score 3.00
- Grade Equal-Weight
- Symbol (ORGO)
- Company Organogenesis Holdings Inc.
- Price $2.87
- Changes Percentage (-0.69%)
- Change -$0.02
- Day Low $2.84
- Day High $2.96
- Year High $4.71
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.04
- Trailing P/E Ratio 68.75
- Forward P/E Ratio 68.75
- P/E Growth 68.75
- Net Income $4.95 M
Income Statement
Quarterly
Annual
Latest News of ORGO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A catch? Not a catch? The Miami-Virginia Tech ending won't be forgotten by either side
Miami quarterback Cam Ward and Virginia Tech quarterback Kyron Drones, close cousins and training partners, faced off in a dramatic game won by Miami. The disputed final play led to a long review, ult...
By CBS News | 2 days ago -
Here are the biggest 'Saturday Night Live' feuds you forgot existed
Discover the biggest feuds in "Saturday Night Live" history, from Bill Murray vs. Chevy Chase to Dana Carvey vs. Mike Myers. As Season 50 approaches, let's revisit the drama that unfolded both on and ...
By New York Post | 3 days ago -
Max Shalunov is officially no longer a Blackhawks prospect, but he won't be soon forgotten
Max Shalunov, a Chicago Blackhawks prospect, was removed from the NHL's reserve list, signaling the end of an era. Despite once being a potential NHL player, Shalunov's dream likely won't materialize....
By The New York Times | 3 days ago
